Keymed Biosciences Inc.
HKEX:2162.HK
43.55 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 354.095 | 100.063 | 110.269 | 0 | 0 |
| Cost of Revenue
| 36.878 | 2.585 | 17.2 | 0 | 0 |
| Gross Profit
| 317.217 | 97.478 | 93.069 | 0 | 0 |
| Gross Profit Ratio
| 0.896 | 0.974 | 0.844 | 0 | 0 |
| Reseach & Development Expenses
| 596.282 | 507.374 | 358.156 | 127.4 | 64.812 |
| General & Administrative Expenses
| 177.006 | 133.912 | 130.386 | 8.936 | 7.746 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 177.006 | 133.912 | 130.386 | 8.936 | 7.746 |
| Other Expenses
| 1.192 | -65.544 | -45.654 | -0.869 | -5.352 |
| Operating Expenses
| 752.017 | 575.742 | 442.888 | 135.467 | 67.206 |
| Operating Income
| -457.43 | -295.378 | -3,881.499 | -804.701 | -162.198 |
| Operating Income Ratio
| -1.292 | -2.952 | -35.2 | 0 | 0 |
| Total Other Income Expenses Net
| 101.242 | -8.219 | -11.133 | -14.147 | -5.314 |
| Income Before Tax
| -356.188 | -303.597 | -3,892.632 | -818.848 | -167.512 |
| Income Before Tax Ratio
| -1.006 | -3.034 | -35.301 | 0 | 0 |
| Income Tax Expense
| 1.597 | 4.518 | 5.81 | 13.882 | 5.314 |
| Net Income
| -359.357 | -308.115 | -3,898.442 | -832.73 | -172.826 |
| Net Income Ratio
| -1.015 | -3.079 | -35.354 | 0 | 0 |
| EPS
| -1.37 | -1.18 | -24.24 | -3.07 | -0.64 |
| EPS Diluted
| -1.37 | -1.18 | -24.24 | -3.07 | -0.64 |
| EBITDA
| -269.768 | -259.255 | -3,860.48 | -785.709 | -149.899 |
| EBITDA Ratio
| -0.762 | -2.591 | -35.01 | 0 | 0 |